Zur Rose Group AG

  • ISIN: CH0042615283
  • Land: Schweiz

Nachricht vom 13.01.2021 | 16:10

Zur Rose vindicated after court finds CEO Walter Oberhänsli not guilty

EQS Group-News: Zur Rose Group AG / Key word(s): Legal Matter
13.01.2021 / 16:10

Press release

Zur Rose vindicated after court finds CEO Walter Oberhänsli not guilty

The Frauenfeld district court today found Walter Oberhänsli not guilty on all charges in connection with the prosecution for mail-order distribution of non-prescription drugs and rewarding doctors for issuing electronic prescriptions. The prosecution was based on a report of a criminal offence lodged by PharmaSuisse, the Swiss Pharmacists Association.

"I am delighted at the verdict from the Frauenfeld district court", said Walter Oberhänsli. "But actually there is much more at stake here: as a company we feel vindicated by this ruling in our ambition to make healthcare cheaper, more accessible and safer with digitalisation. The urgent need for further digitalisation in the Swiss healthcare system was made very apparent during the coronavirus crisis. The effective ban on mail-order distribution of non-prescription drugs is increasingly becoming a historical relict that has to be seen as anachronistic in the current environment and positively harmful to health when the coronavirus is rampant. What is urgently required now is the mandatory introduction of electronic prescriptions; numerous studies have shown that these increase patient safety and avoid the follow-up costs incurred as a result of media breaks and the absence of digital processes. For all these reasons we will continue to work for high-quality, safe and low-cost supply of pharmaceuticals."

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Agenda
21 January 2021 Sales 2020
18 March 2021 2020 Full-Year Results
20 April 2021 First Quarter Trading Update
29 April 2021 Annual General Meeting
19 August 2021 Half-Year Results
21 October 2021 Q3 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around ten million active customers in core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.



End of Media Release



show this

GBC-Fokusbox

International School Augsburg (ISA) – erste Schule in Deutschland geht an die Börse

Die International School Augsburg – ISA- gemeinnützige AG geht als erste Schule in Deutschland an die Börse und macht damit erstmals das Thema „Bildung“ unter ESG-Kriterien investierbar. Mit dem geplanten Emissionserlös soll ein Campus-Neubau finanziert werden, um die hohe Nachfrage bedienen zu können. In unserer Researchstudie haben wir die hohe Bedeutung der ISA für den regionalen Wirtschaftsstandort, eine hohe Stabilität der Geschäftsentwicklung sowie hohe Sicherheiten durch vorhandene Sachwerte ermittelt. Das Rating lautet KAUFEN.

News im Fokus

Fresenius Medical Care AG & Co. KGaA veröffentlicht Form 20-F für das Geschäftsjahr 2020

24. Februar 2021, 10:51

Aktueller Webcast

TK Elevator GmbH

Release of Annual Report 2019/2020 and Trading Update/Flash Reporting Q1 2020/2021

26. Februar 2021

Aktuelle Research-Studie

Nynomic AG

Original-Research: Nynomic AG (von Montega AG): Kaufen

25. Februar 2021